These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 24589868)

  • 1. II. Looking into the future of platelet transfusion in the presence of P2Y(12) inhibitors.
    Tanaka KA; Subramaniam K
    Br J Anaesth; 2014 May; 112(5):780-4. PubMed ID: 24589868
    [No Abstract]   [Full Text] [Related]  

  • 2. Mode of action of P2Y(12 ) antagonists as inhibitors of platelet function.
    Iyú D; Glenn JR; White AE; Fox SC; van Giezen H; Nylander S; Heptinstall S
    Thromb Haemost; 2011 Jan; 105(1):96-106. PubMed ID: 20941457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inefficacy of Platelet Transfusion in a Heart Transplant Patient Under Continuous Ticagrelor.
    Filaire L; Pham DT; d'Ostrevy N; Tran HT; Camilleri L; Azarnoush K
    J Cardiothorac Vasc Anesth; 2017 Oct; 31(5):1776-1778. PubMed ID: 28625754
    [No Abstract]   [Full Text] [Related]  

  • 4. How do I transfuse platelets (PLTs) to reverse anti-PLT drug effect?
    Sarode R
    Transfusion; 2012 Apr; 52(4):695-701; quiz 694. PubMed ID: 21854398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.
    Iyú D; Glenn JR; White AE; Fox SC; Dovlatova N; Heptinstall S
    Platelets; 2011; 22(7):504-15. PubMed ID: 21591981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Looking beyond antiplatelet effect of P2Y12 inhibitors: is there anything to see?
    Sabbah M; Lønborg J; Engstrøm T; Nepper-Christensen L
    Int J Cardiol; 2020 Dec; 320():25. PubMed ID: 32652211
    [No Abstract]   [Full Text] [Related]  

  • 7. Clopidogrel: interactions with the P2Y12 receptor and clinical relevance.
    Dorsam RT; Murugappan S; Ding Z; Kunapuli SP
    Hematology; 2003 Dec; 8(6):359-65. PubMed ID: 14668029
    [No Abstract]   [Full Text] [Related]  

  • 8. New antiplatelet agents.
    Samama M
    Acta Anaesthesiol Belg; 2010; 61(3):127. PubMed ID: 21268565
    [No Abstract]   [Full Text] [Related]  

  • 9. Prasugrel resistance: fact or fiction.
    Alexopoulos D
    Platelets; 2012; 23(2):83-90. PubMed ID: 21787175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prasugrel offers consistent platelet control in appropriate patients requiring treatment.
    Aalbers J
    Cardiovasc J Afr; 2011; 22(2):107, 109. PubMed ID: 21556460
    [No Abstract]   [Full Text] [Related]  

  • 11. New anticoagulants--how do they work?
    Kozek S
    Acta Anaesthesiol Belg; 2010; 61(3):125. PubMed ID: 21268564
    [No Abstract]   [Full Text] [Related]  

  • 12. A clopidogrel-insensitive inducible pool of P2Y12 receptors contributes to thrombus formation: inhibition by elinogrel, a direct-acting, reversible P2Y12 antagonist.
    Haberstock-Debic H; Andre P; Mills S; Phillips DR; Conley PB
    J Pharmacol Exp Ther; 2011 Oct; 339(1):54-61. PubMed ID: 21730013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspirin, P2Y12 blockers, cilostazol, PAR-1 blockers and emerging antiplatelet therapies: can biomarkers guide clinical development and practice?
    Menown IB
    Biomark Med; 2011 Feb; 5(1):1-3. PubMed ID: 21319960
    [No Abstract]   [Full Text] [Related]  

  • 14. The importance of endothelium-derived mediators to the efficacy of dual anti-platelet therapy.
    Warner TD; Armstrong PC; Chan MV; Knowles RB
    Expert Rev Hematol; 2016 Mar; 9(3):223-5. PubMed ID: 26822235
    [No Abstract]   [Full Text] [Related]  

  • 15. Modification of the VerifyNow® P2Y12 test BASE channel to accommodate high levels of P2Y(12) antagonism.
    Jakubowski JA; Zhou C; Egan B; Wells M; Kotob-Yahfoufi M; Sugidachi A; Dahlen JR
    Platelets; 2011; 22(8):619-25. PubMed ID: 21639823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional testing methods for the antiplatelet effect of P2Y12 receptor antagonists.
    Price MJ; Barker CM
    Biomark Med; 2011 Feb; 5(1):43-51. PubMed ID: 21319964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Synthesis of thienopyridine derivatives and its anti-platelet activity in vivo].
    Zhou YS; Wang PB; Liu Y; Chen JF; Yue N; Liu DK
    Yao Xue Xue Bao; 2011 Jan; 46(1):70-4. PubMed ID: 21465811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Smoking status and the effects of antiplatelet drugs.
    Hirschl MM
    BMJ; 2013 Oct; 347():f5909. PubMed ID: 24473451
    [No Abstract]   [Full Text] [Related]  

  • 19. Uridine Triphosphate Thio Analogues Inhibit Platelet P2Y
    Gündüz D; Tanislav C; Sedding D; Parahuleva M; Santoso S; Troidl C; Hamm CW; Aslam M
    Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28146050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ticagrelor: a novel oral antiplatelet agent.
    Huang NS; Master HH; Fusco JA; Park ZH
    Consult Pharm; 2010 Nov; 25(11):745-55. PubMed ID: 21138823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.